New perspectives on screening and early detection of endometrial cancer.
biomarkers
early detection
endometrial cancer
genomics
pap smears
screening
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 12 2019
15 12 2019
Historique:
received:
15
02
2019
revised:
27
05
2019
accepted:
31
05
2019
pubmed:
15
6
2019
medline:
31
1
2020
entrez:
15
6
2019
Statut:
ppublish
Résumé
Due to the anatomical continuity of the uterine cavity with the cervix, genomic exploitation of material from routine Pap smears and other noninvasive sampling methods represent a unique opportunity to detect signs of disease using biological material shed from the upper genital tract. Recent research findings offer a promising perspective in the detection of endometrial cancer, but certain questions need to be addressed in order to accelerate the implementation of novel technologies in a routine screening or clinical setting. We discuss here new perspectives on detection of endometrial cancer using genomic and other biomarkers in minimally invasive sampling methods with a special focus on public health classic screening criteria, highlighting current gaps in knowledge.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3194-3206Informations de copyright
© 2019 UICC.
Références
Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet 2016;387:1094-108.
Wang Y, Li L, Douville C, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med 2018;10:eaap8793.
Andermann A. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317-9.
Ferlay J, Ervik M, Lam F, et al. GLOBOCAN 2018. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer, 2018 Available from: https://gco.iarc.fr/today.
Torre LA, Islami F, Siegel RL, et al. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 2017;26:444-57.
Tarney CM, Tian C, Wang G, et al. Impact of age at diagnosis on racial disparities in endometrial cancer patients. Gynecol Oncol 2018;149:12-21.
Guttery DS, Blighe K, Polymeros K, et al. Racial differences in endometrial cancer molecular portraits in the cancer genome atlas. Oncotarget 2018;9:17093-103.
Schlumbrecht M, Baeker Bispo JA, Balise RR, et al. Variation in type II endometrial cancer risk by Hispanic subpopulation: an exploratory analysis. Gynecol Oncol 2017;147:329-33.
Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113:299-310.
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
Narice BF, Delaney B, Dickson JM. Endometrial sampling in low-risk patients with abnormal uterine bleeding: a systematic review and meta-synthesis. BMC Fam Pract 2018;19:135.
Visser NCM, Reijnen C, Massuger LFAG, et al. Accuracy of endometrial sampling in endometrial carcinoma: a systematic review and meta-analysis. Obstet Gynecol 2017;130:803-13.
Reijnen C, Visser NCM, Bulten J, et al. Diagnostic accuracy of endometrial biopsy in relation to the amount of tissue. J Clin Pathol 2017;70:941-6.
Du J, Li Y, Lv S, et al. Endometrial sampling devices for early diagnosis of endometrial lesions. J Cancer Res Clin Oncol 2016;142:2515-22.
Tabata T, Yamawaki T, Yabana T, et al. Natural history of endometrial hyperplasia. Study of 77 patients. Arch Gynecol Obstet 2001;265:85-8.
Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:403-12.
Baak JP, Mutter GL, Robboy S, et al. In endometrial hyperplasias, the molecular-genetics and morphometry-based EIN classification more accurately predicts cancer-progression than the WHO94. Cancer 2005;103:2304-12.
Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a gynecologic oncology group study. Cancer 2006;106:812-9.
Lacey JV, Ioffe OB, Ronnett BM, et al. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer 2008;98:45-53.
Lacey JV, Sherman ME, Rush BB, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010;28:788-92.
Sanderson PA, Critchley HOD, Williams ARW, et al. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update 2017;23:232-54.
Raffone A, Travaglino A, Saccone G, et al. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet 2019;299:1233-42.
Zheng W, Xiang L, Fadare O, et al. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 2011;35:e1-14.
Fadare O, Zheng W. Endometrial glandular dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of type II endometrial cancers. Diagn Pathol 2008;3:6.
Vierkoetter KR, Kagami LAT, Ahn HJ, et al. Loss of mismatch repair protein expression in unselected endometrial adenocarcinoma precursor lesions. Int J Gynecol Cancer 2016;26:228-32.
Maksem JA, Robboy SJ, Bishop JW, et al. Endometrial precancer. In: Meiers I, Bishop JW, Robboy SJ, et al., eds Endometrial cytology with tissue correlations. Essentials in cytopathology, vol. 7. Boston, MA: Springer, 2009. 189-230.
Berg A, Hoivik EA, Mjøs S, et al. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget 2015;6:1327-39.
Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol 2002;55:326-31.
Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol 2009;2:411-32.
Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 2008;14:2263-9.
Sun H, Enomoto T, Fujita M, et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 2001;115:32-8.
Mota A, Colás E, García-Sanz P, et al. Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. Mod Pathol 2017;30:134-45.
van der Putten LJM, van Hoof R, Tops BBJ, et al. Molecular profiles of benign and (pre)malignant endometrial lesions. Carcinogenesis 2017;38:329-35.
Kurman RJ. WHO classification of tumours of female reproductive organs, 4th edn. Lyon: International Agency for Research on Cancer, 2014. 307.
Gibson WJ, Hoivik EA, Halle MK, et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet 2016;48:848-55.
Nair N, Camacho-Vanegas O, Rykunov D, et al. Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: a prospective cross-sectional study. PLoS Med 2016;13:e1002206.
Milholland B, Auton A, Suh Y, et al. Age-related somatic mutations in the cancer genome. Oncotarget 2015;6:24627-35.
Martignetti JA, Pandya D, Nagarsheth N, et al. Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy. Cold Spring Harb Mol Case Stud 2018;4:a003269.
Lacey JV, Mutter GL, Ronnett BM, et al. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 2008;68:6014-20.
Mutter GL, Monte NM, Neuberg D, et al. Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues. Cancer Res 2014;74:2796-802.
Travaglino A, Raffone A, Saccone G, et al. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2018;231:104-10.
Raffone A, Travaglino A, Saccone G, et al. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 2019;299:1511-24.
Widschwendter M, Jones A, Evans I, et al. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol 2018;15:292-309.
Wentzensen N, Bakkum-Gamez JN, Killian JK, et al. Discovery and validation of methylation markers for endometrial cancer. Int J Cancer 2014;135:1860-8.
Esteller M, Catasus L, Matias-Guiu X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999;155:1767-72.
Jones A, Teschendorff AE, Li Q, et al. Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med 2013;10:e1001551.
Hoivik EA, Kusonmano K, Halle MK, et al. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget 2014;5:1052-61.
Bakkum-Gamez JN, Wentzensen N, Maurer MJ, et al. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol Oncol 2015;137:14-22.
Zhou L, Meng Z, Wu Y, et al. Prediction of endometrial carcinogenesis probability while diagnosed as atypical endometrial hyperplasia: a new risk model based on age, CA199 and CA125 assay. Eur J Obstet Gynecol Reprod Biol 2014;183:5-9.
Martinez-Garcia E, Lopez-Gil C, Campoy I, et al. Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Rev Proteomics 2018;15:81-99.
Frick AC, Walters MD, Larkin KS, et al. Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse. Am J Obstet Gynecol 2010;202:507.e1-4.
Wong S, Ratner E, Buza N. Intraoperative evaluation of prophylactic hysterectomy and Salpingo-oophorectomy specimens in hereditary gynecologic cancer syndromes. Histopathology 2018;73:109-23.
Clarke MA, Long BJ, ADM M, et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med 2018;178:1210-22.
Bagaria M, Shields E, Bakkum-Gamez JN. Novel approaches to early detection of endometrial cancer. Curr Opin Obstet Gynecol 2017;29:40-6.
Wittenberger T, Sleigh S, Reisel D, et al. DNA methylation markers for early detection of women's cancer: promise and challenges. Epigenomics 2014;6:311-27.
Hüsing A, Dossus L, Ferrari P, et al. An epidemiological model for prediction of endometrial cancer risk in Europe. Eur J Epidemiol 2016;31:51-60.
Pfeiffer RM, Park Y, Kreimer AR, et al. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med 2013;10:e1001492.
Fortner RT, Hüsing A, Kühn T, et al. Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort. Int J Cancer 2017;140:1317-23.
Alblas M, Velt KB, Pashayan N, et al. Prediction models for endometrial cancer for the general population or symptomatic women: a systematic review. Crit Rev Oncol Hematol 2018;126:92-9.
Giannella L, Mfuta K, Setti T, et al. A risk-scoring model for the prediction of endometrial cancer among symptomatic postmenopausal women with endometrial thickness >4 mm. Biomed Res Int 2014;2014:130569.
Burbos N, Musonda P, Duncan TJ, et al. Estimating the risk of endometrial cancer in symptomatic postmenopausal women: a novel clinical prediction model based on patients’ characteristics. Int J Gynecol Cancer 2011;21:500-6.
Wong AS-W, Cheung CW, Fung LW-Y, et al. Development and validation of prediction models for endometrial cancer in postmenopausal bleeding. Eur J Obstet Gynecol Reprod Biol 2016;203:220-4.
Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004;24:558-65.
Calis P, Yuce K, Basaran D, et al. Assessment of cervicovaginal cancer antigen 125 levels: a preliminary study for endometrial cancer screening. Gynecol Obstet Invest 2016;81:518-22.
Seebacher V, Schmid M, Polterauer S, et al. The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer 2009;9:460.
Kimura T, Kamiura S, Yamamoto T, et al. Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynaecol Obstet 2004;85:145-50.
Ryan NAJ, Blake D, Cabrera-Dandy M, et al. The prevalence of lynch syndrome in women with endometrial cancer: a systematic review protocol. Syst Rev 2018;7:121.
Møller P, Seppälä T, Bernstein I, et al. Cancer incidence and survival in lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective lynch syndrome database. Gut 2017;66:464-72.
Niskakoski A, Pasanen A, Lassus H, et al. Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from lynch syndrome surveillance. Mod Pathol 2018;31:1291-301.
Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015;110:223-62. quiz 263.
Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Dis Colon Rectum 2014;57:1025-48.
Vasen HFA, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62:812-23.
Balmana J, Balaguer F, Cervantes A, et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2013;24:vi73-80.
Crosbie EJ, Ryan NAJ, Arends MJ, et al. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med 2019. https://www.ncbi.nlm.nih.gov/pubmed/30918358
Ryan NAJ, Morris J, Green K, et al. Association of Mismatch Repair Mutation with age at cancer onset in lynch syndrome: implications for stratified surveillance strategies. JAMA Oncol 2017;3:1702-6.
Renkonen-Sinisalo L, Bützow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007;120:821-4.
Grosse Y, Baan R, Straif K, et al. A review of human carcinogens-part a: pharmaceuticals. Lancet Oncol 2009;10:13-4.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and bowel project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet Lond Engl 1989;1:117-20.
Chlebowski RT, Haque R, Hedlin H, et al. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat 2015;154:609-16.
Chlebowski RT, Schottinger JE, Shi J, et al. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer 2015;121:2147-55.
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol Off J Am Soc Clin Oncol 2016;34:4225-30.
Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ 2007;335:1134.
Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer 2018. https://www.ncbi.nlm.nih.gov/pubmed/30387875
Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet Lond Engl 2011;377:557-67.
Lortet-Tieulent J, Ferlay J, Bray F, et al. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst 2018;110:354-61.
Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013;31:2607-18.
Khoury MJ, Iademarco MF, Riley WT. Precision public health for the era of precision medicine. Am J Prev Med 2016;50:398-401.
Muinelo-Romay L, Casas-Arozamena C, Abal M, et al. Liquid biopsy in endometrial cancer: new opportunities for personalized oncology. Int J Mol Sci 2018;19:2311.
Linkov F, Yurkovetsky Z, Taioli E, et al. Endometrial cancer: multiplexed Luminex approaches for early detection. Expert Opin Med Diagn 2008;2:527-37.
Austin RM. George Papanicolaou's efforts to develop novel cytologic methods for the early diagnosis of endometrial carcinoma. Acta Cytol 2017;61:281-98.
Papanicolaou GN, Maddi FV. Diagnostic value of cells of endometrial and ovarian origin in human tissue cultures. Acta Cytol 1961;5:1-16.
Amkreutz LCM, Pijnenborg JMA, Joosten DWL, et al. Contribution of cervical cytology in the diagnostic work-up of patients with endometrial cancer. Cytopathology 2018;29:63-70.
Sams SB, Currens HS, Raab SS. Liquid-based Papanicolaou tests in endometrial carcinoma diagnosis: performance, error root cause analysis, and quality improvement. Am J Clin Pathol 2012;137:248-54.
Huang R-L, Su P-H, Liao Y-P, et al. Integrated Epigenomics analysis reveals a DNA methylation panel for endometrial cancer detection using cervical scrapings. Clin Cancer Res 2017;23:263-72.
Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013;5:167ra4-4.
Chang CC, Wang HC, Liao YP, et al. The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings. J Gynecol Oncol 2018;29:e17.
De Strooper LMA, van Zummeren M, Steenbergen RDM, et al. CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol 2014;67:1067-71.
Kim G-E, Kweon S-S, Lee JS, et al. Quantitative assessment of DNA methylation for the detection of cervical and endometrial adenocarcinomas in liquid-based cytology specimens. Anal Quant Cytopathol Histopathol 2012;34:195-203.
He S-M, Xing F, Sui H, et al. Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer. Med Sci Monit Int Med J Exp Clin Res 2011;17:CR618-25.
Heng S, Stephens AN, Jobling TW, et al. Measuring PC activity in endocervical swab may provide a simple and non-invasive method to detect endometrial cancer in post-menopausal women. Oncotarget 2016;7:46573-8.
Martinez-Garcia E, Lesur A, Devis L, et al. Targeted proteomics identifies proteomic signatures in liquid biopsies of the endometrium to diagnose endometrial cancer and assist in the prediction of the optimal surgical treatment. Clin Cancer Res 2017;23:6458-67.
Koss LG, Schreiber K, Oberlander SG, et al. Screening of asymptomatic women for endometrial cancer. CA Cancer J Clin 1981;31:300-17.
Koss LG, Schreiber K, Oberlander G, et al. Screening of asymptomatic women for endometrial cancer. Obstet Gynecol 1981;57:681-91.
Fambrini M, Sorbi F, Sisti G, et al. Endometrial carcinoma in high-risk populations: is it time to consider a screening policy? Cytopathology 2014;25:71-7.
Nakagawa-Okamura C, Sato S, Tsuji I, et al. Effectiveness of mass screening for endometrial cancer. Acta Cytol 2002;46:277-83.
Fiegl H, Gattringer C, Widschwendter A, et al. Methylated DNA collected by tampons-a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 2004;13:882-8.
Doufekas K, Zheng SC, Ghazali S, et al. DNA methylation signatures in vaginal fluid samples for detection of cervical and endometrial cancer. Int J Gynecol Cancer 2016. https://www.ncbi.nlm.nih.gov/pubmed/27258725
Ketelaars PJW, Bosgraaf RP, Siebers AG, et al. High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: results of the VERA study. Prev Med 2017;101:96-101.
Havrilesky LJ, Maxwell GL, Myers ER. Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol 2009;200:640.e1-8.
Diaz M, de Sanjosé S, Bosch FX, et al. Present challenges in cervical cancer prevention: answers from cost-effectiveness analyses. Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol 2018;23:484-94.
Bosch FX, Robles C, Díaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2016;13:119-32.